Our objective was to analyze the potential advantage of combining an intraaortic balloon pump with a transthoracic Hemopum p device (Medtronic, Inc., Minneapolis, Minn.) (Nimbus Medical, Inc., Rancho Cordova, Calif.). Methods: Twelve sheep underwent implantation of a transthoracic Hemopump device and an intraaortic balloon pump, In the first series (n = 6), we analyzed the influence of the counterpulsation on the performance of the Hemopump device. In the second group (n = 6), hemodynamic changes, myocardial wall thickening, organ perfusion, and myocardial perfusion (determined with colored microspheres) were ana, lyzed under the following conditions: (1) control situation, (2) during application of coronary stenosis, (3) during support with the Hemopump device, and (4) during support with the Hemopump device combined with intraaortie balloon pump support. Results: In the first series, we found that addition of counterpulsation reduced output with the Hemopump device by 11.1% -6%. In the second series, it was shown that coronary stenosis significantly reduced contractility (rate of pressure change and wall thickening) but did not cause hemodynamic collapse. Myocardial blood flow was significantly reduced in the poststenotic subendoeardial regions (mean subendocardial blood flow dropped from 78 -33 to 24 --_ 17 m!/min/100 gm; p = 0.0486). Support with the Hemopump device alone improved the ratio of subendocardial to subepicardial blood flow, but endocardial underperfusion remained (analysi s of variance, p < 0.001). The Hemopump device with an intraaortic balloon pump completely restored perfusion in poststenotic regions. Peripheral organ perfusion did not change during ischemia or mechanical support, Conclusions: The association of balloon counterpulsation with the Hemopump device reduces the Hemopump output by 11% and increases myocardial blood flow to ischemic regions. Perfusion to peripheral organs remains unaltered. The transthoracic Hemopump device combined with an intraaortic balloon pump is an ideal support system for the ischemic, failing heart. (J Thorac
the left ventricular cavity and expels it in the ascending aorta. The most frequently used and most reliable cannula is the transthoracic cannula, which is introduced through a graft sutured on the ascending aorta. This transthoracic Hemopump device is a powerful pump, with a rotational speed of 26,000 rpm producing a maximum pump flow of 5.1 L/min. The performance of this nonpulsatile blood pump, however, is dependent on the actual pressure differences between inflow and outflow of this pump. With a mean aortic pressure of 70 mm Hg in the clinical situation, the pump thus produces approximately 4 L/rain. The Hemopump device increases myocardial blood flow by decreasing ventricular end-diastolic pressure and by increasing mean aortic blood pressure. 5 Most clinicians prefer the less invasive IABP as the first choice for mechanical support in cases of low cardiac output because the use of the transthoracic Hemopump device requires a sternotomy for both insertion and removal. The transthoracic Hemopump device is considered a "second-line" mechanical support device for patients who do not recover despite the use of an IABP. An IABP is thus often already in place when the Hemopump device is introduced. The transthoracic Hemopump device and the IABP inserted through the groin can easily be combined, so we studied whether the combination of these devices could be beneficial.
Materials and methods
Animal instrumentation. Twelve sheep (mean weight 69.8 _+ 15 kg) were anesthetized with intravenous pentobarbital (3 mg/kg), intubated, and mechanically ventilated with 60% oxygen. Anesthesia was maintained with 0.5% to 2% halothane, and 0.2 mg/kg piritramide was administered every 40 minutes. All animals received humane care in compliance with the "Guide for the Care of and Use of Laboratory Animals" prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health NIH Publication No. 86-23, revised 1985.
A triple-lumen central venous line was inserted into the jugular vein, and a fluid-filled pressure catheter was placed in the carotid artery. Both were placed through a cutdown in the left side of the neck. Left thoracotomy was performed through the fifth intercostal space. Heparin was administered at 300 U/kg. When the pericardium was opened, 100 mg lidocaine (Xylocaine) was administered. The left groin was incised and a 40 ml intraaortic balloon (Datascope Inc., Paramus, N.J.) was introduced through the femoral artery. The balloon was positioned in the descending thoracic aorta. A fluid-filled pressure line was inserted in the left atrium and a Mikro-Tip catheter transducer (Millar Instruments, Inc., Houston, Tex.) was placed in the left ventricle through the apex. All pressure transducers were connected to a Triton pressure module (Triton, San Diego, Calif.). Two different instrumentation procedures were performed: one group of six animals was implanted with instruments for accurate measurements of flow through the Hemopump device (protocol 1); the other group of six animal s was implanted with instruments for hemodynamic and organ perfusion analysis (protocol 2). Protocol 1. In the first group of six animals, the ascending aorta was encircled and a 12 mm Dacron polyester fabric Y-graft was sutured to the aorta. A second graft of the same size was sutured to the descending aorta, and the grafts were interconnected with an inflow electromagnetic flowmeter of 3/8 inch (Cliniflow II, model FM 701 D; Carolina Medical Electronics, Inc., N.C.; Fig. 1) . A transthoracic Hemopump cannula was transvalvularly placed in the left ventricle through the side arm of the Y-graft. The side arm was occluded by the occluders provided with the Hemopump device, diverting the produced Hemopump flow through the flowmeter back to the descending aorta (Fig. 1) . The metal outflow part of the Hemopump device was positioned in the graft, and a suture around the graft secured the pump in this position and prevented leakage of flow along the Hemopump device into the ascending aorta. Protocol 2. In the second group of six animals, a 12 mm Dacron polyester fabric graft was sutured to the ascending aorta for introduction of the transthoracic Hemopump cannula. The lateral branch of the left coronary artery was visualized in the atrioventricular groove near its origin. An electromagnetic flow probe was positioned around it and connected to a Nyhon Kohden (Tokyo, Japan) flowmeter. A second electromagnetic flowmeter (model 1401; Skalar, Delft, The Netherlands) was placed around the pulmonary artery for continuous measurement of cardiac output. A set of ultrasonic transit-time crystals consisting of one endocardial crystal and one epicardial crystal was sutured to the posterolateral region of the heart. These crystals were connected to a sonomicrometer module (Triton, San Diego, Calif.) for measurement of wall thickening.
Experimental protocols. Measurements were repeated with the balloon pump working in an electrocardiographically triggered 1-to-1 mode. At the end of the experiment, the heart was opened to confirm the intraventricular position of the Hemopump.
In the second protocol (n = 6), we focused on hemodynamic changes, organ perfusion, and myocardial perfusion during Hemopump support alone and with IABP support. Myocardial wall thickening, left ventricular pressure, first derivative of the left ventricular pressure, arterial blood pressure, coronary flow, cardiac output, and left atrial pressure were continuously recorded on an eightchannel chart recorder (Nyhon Kohden). After stabilization, a first set of colored microspheres was injected into the left atrium (Fig. 2) .
A stenosis was applied to the lateral branch of the left coronary artery. This stenosis was tightened until a drop of 50% in the baseline coronary flow in that vessel occurred and was then left untouched for 10 minutes. After 5 minutes of stenosis, a second set of colored microspheres was injected through the left atrial catheter and the mechanical support was started (Fig. 2) . Five minutes later, a third injection of microspheres was given. The stenosis was relieved and time was allowed for all parameters to stabilize. Then the same stenosis was applied again and a fourth set of microspheres was injected after 5 minutes. This time the second condition of mechanical support was started, and 5 minutes later the fifth set of microspheres was given. The modes of mechanical support (Hemopump device alone and Hemopump device with IABP) were alternated in sequence of use.
Myocardial and organ flow measurement with colored microspheres. Nine million 15 mm diameter polystyrene microspheres of five different colors (white, red, yellow, blue, and violet) were injected on five different occasions during the experiment. The microspheres were injected in a volume of 3 ml over 30 seconds. Arterial reference blood was withdrawn during 90 seconds from the aorta at a flow rate of 10 ml/min. On termination of the experiment, 1 gm tissue samples were isolated from lungs, cerebrum, cerebellum, spleen, liver, pancreas, stomach, small bowel, large bowel, renal cortex, renal medulla, skin, and muscles.
The hearts were removed, trimmed of excess fat, and cut in five slices along the short axis. Each slice was then cut and unrolled into a myocardial strip (Fig. 3) . Three right ventricular and nine left ventricular regions were identified and biopsy samples were taken from each zone from the subepicardium as well as from the subendocardium. The second slice (counting from the base of the heart) from each animal was processed for quantification of the colored microsphere content. The colored microsphere content was determined by the methods described by Kowallik of the data covered 1 second of data per log. Thus, depending on the animal's heart rate, one or two heartbeats were analyzed at a time. Data were analyzed with the Statistica statistical software package (Statsoft Inc., Tulsa, Okla.). Organ flows and hemodynamic data are presented as means plus or minus the standard deviation. Myocardial blood flow values in different zones of the heart were analyzed with analysis of variance (ANOVA) for repeated measurements. Hemodynamic data were analyzed with ANOVA for repeated measurements and with a one-way multivariate ANOVA for differences between modes of mechanical support. Paired comparisons with control values were performed with the twotailed paired Student's t test.
Results
Influence of the IABP on the performance of the Hemopump device. The IABP reduced the performance of the Hemopump device. Fig. 4 shows the mean flow produced at the different rotational speeds by the Hemopump device and by the combination of the Hemopump device with the IABP. In the control situation, with the Hemopump device switched off, a backflow was measured through the cannula (-0.39 L/rain). This backflow was further increased to -0.49 L/rain by the IABP (increase of the baekflow by 20%). When the Hemopump device was working, the IABP reduced the flow by 11.1% at all rotational speeds. This reduction of the Hemopump flow by the IABP was only significant in the control situation and at low speed. The increased diastolic blood pressure increased the pressure head of the Hemopump device and reduced diastolic pump flow. This is shown in Fig. 5 . With the IABP in a 1-in-2 frequency, one can clearly identify the reduced diastolic flow production in the IABP-assisted beat versus the unassisted beat.
Hemodynamic changes, unloading, and contractility. Systolic arterial blood pressure, diastolic arterial blood pressure, cardiac output, and left atrial pressure are shown in Fig. 6 . The influence of the coronary stenosis on overall hemodynamics was mild. There was no significant drop in total cardiac output or perfusion pressure. The use of the Hemopump device significantly increased the diastolic blood pressure (from 55 _+ 15 to 75 + 22 mm Hg; p = 0.0088), but the combination of Hemopump device and IABP was even more effective in increasing the diastolic blood pressure (from 56 _+ 11 to 88 _+ 6 mm Hg; p < 0.00001). Left atrial pressures were increased during ischemia and reduced as soon as the mechanical support commenced. There was no difference in the reduction of the left atrial pressure between modes of mechanical support.
The maximum and minimum values of the first derivative of the left ventricular pressure changed significantly during the experiment (Fig. 7) . There was a severe drop in contractility when the stenosis was applied, and the heart was further unloaded when the the splenic perfusion data to be clinically useful. There were no statistically significant changes in organ perfusion between the control values and the ischemic values (hemodynamics did not change). Also, the mechanical support did not alter peripheral organ perfusion. There was no difference in peripheral organ perfusion between the Hemopump device alone and the combination of Hemopump device with IABP. Myocardial perfusion. Myocardial perfusion was measured by the colored microsphere technique in different regions of the heart, both in the subendocardium and in the subepicardium. We thus obtained the subendocardial blood flow, the subepicardial blood flow, and the ratio of subendocardial to subepicardial blood flow. Figs. 9 through 11 show the means of the different animals in the same myocardial regions for three different conditions: (1) control value before the stenosis was applied, (2) the ischemic value measured 5 minutes after application of the stenosis, and (3) the assisted value measured 5 minutes after the start of mechanical support (with the stenosis still in place). These curves are presented for subendocardial blood flow (Fig. 9) , subepicardial blood flow (Fig. 10) , and the ratio of subendocardial to subepicardial flow ( Fig. 11) for assistance with the Hemopump device alone and with the IABP. After application of the stenosis on the lateral branch of the left coronary artery, the myocardial blood flow was statistically significantly changed in the subendocardial regions (ANOVA, p < 0.001). This drop in blood flow was seen in the posterolateral zones of the left ventricle (Fig. 9) . The mean subendocardial blood flow in these regions dropped from 78 = 33 to 24 z 17 ml/min/100 gm (p = 0.0486) The changes in the epicardial blood flow (Fig. 10) were not statistically significant (ANOVA, p = 0.0704; mean from 64 --26 to 57 -+ 40 ml/min/100 gm,p > 0.2). As a consequence, the ratio of subendocardial to subepicardial blood flow (Fig. 11 ) was significantly reduced (ANOVA. p < For the subendocardial myocardial perfusion, the ANOVA still showed a significant difference from the control situation (p < 0.001; Fig. 9, A) . Support with the combination of the Hemopump device and IABP improved myocardial blood flow to a greater extent (Figs. 9, B, 10 , B, and 11, B). Subendocardial blood flow improved from 24 _+ 17 to 63 + 57 ml/min/100 gm (p > 0.2), epicardial blood flow remains unchanged from 57 -+ 40 to 57 + 44 ml/min/100 gm, and the ratio increased from 0.48 + 0.28 to 1.26 +-1.23 (p -0.1750). As a consequence, there was no significant difference from the control situation (ANOVA for subendocardial flow p > 0.2).
Discussion
Clinical practice has led us to the combined use of the transthoracic Hemopump device and the IABP. 9 In cases of postcardiotomy heart failure, the IABP remains the first choice as a mechanical support device. The device is easily introduced through the femoral artery, has an acceptable complication rate,10,11 and has been shown to be beneficial by increasing myocardial perfusion and reducing left ventricular work. 2-4 In cases of persistent low cardiac output despite pharmacologic support and IABP use, we consider the transthoracic Hemopump device to be the first choice as a left ventricular assist device. This pump is powerful (produces up to 5 L/rain), also is easily introduced, and has proved to be technically reliable, as opposed to the femoral cannulas of the Hemopump device. With the IABP already in place, we introduced the transthoracic Hemopump device and thus created the combination of these devices. We suspected a possible beneficial effect on myocardial flow and were intrigued by the gradual weaning possibilities (first weaning from the Hemopump device and then from IABP).
This experimental study proves our theoretic hypothesis to be sound. First. the increase in diastolic blood pressure created by the IABP reduced the Hemopump flow. Second, the higher diastolic perfusion pressure created an increase in myocardial blood flow in ischemic regions. With the colored microsphere technique, we showed that the Hemopump device and IABP combination returned subendocardial flow in ischemic regions to normal.
Hemodynamic effects. We did not intend to cause hemodynamic collapse by the applied coronary stenosis. On the contrary, our intention was to show the specific effects of the assisted circulation on myocardial perfusion. In a model of cardiogenic shock, the simple increase of cardiac output and arterial blood pressure by the Hemopump device should itself influence the myocardial perfusion. We therefore preferred to create a stenosis with 50% flow reduction, rather than a complete occlusion. In consequence we did not study the effects of cardiogenic shock. Total cardiac output and blood pressure did not significantly change during the created "ischemia." The effects of the Hemopump device alone and with IABP support were therefore minimal; there was no change in total cardiac output. Organ perfusion. We could not identify any effect on peripheral organ perfusion. In this series of experiments, the myocardial stenosis was only applied with the purpose of creating an ischemic subendocardial region. We did not intend to cause myocardial failure and subsequent shock. The so-called "ischemic values"
